Evaluating the Cardiovascular Impact of Genetically Proxied PCSK9 and HMGCR Inhibition in East Asian and European Populations: A Drug-Target Mendelian Randomization Study

Affiliations

• ¹ Section on Clinical Genomics and Experimental Therapeutics (D.B.R., A.S.B., L.A.M., A.H., L.P., J.J., J.W., F.W.L.), National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health (NIH), Bethesda, MD.
• ² NIH-Oxford-Cambridge Scholars Program, University of Oxford, United Kingdom (D.B.R.).
• ³ Medical Research Council Integrative Epidemiology Unit, University of Bristol, United Kingdom (D.B.R., G.D.S.).
• ⁴ Laboratory of Cardiovascular Physiology and Tissue Injury (P.P.), National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health (NIH), Bethesda, MD.
• ⁵ Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, United Kingdom (D.R.).
• ⁶ National Institute for Health and Care Research Oxford Biomedical Research Centre, John Radcliffe Hospital, United Kingdom (D.R.).